Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease

[1]  C. Duyckaerts,et al.  Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease , 2014, Acta Neuropathologica Communications.

[2]  S. Nasoohi,et al.  Author's Personal Copy Behavioural Brain Research Neurorestorative Effect of Fty720 in a Rat Model of Alzheimer's Disease: Comparison with Memantine , 2022 .

[3]  Carlo Caltagirone,et al.  Inverse occurrence of cancer and Alzheimer disease , 2013, Neurology.

[4]  O. Cuvillier,et al.  First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer , 2012, Molecular Cancer Therapeutics.

[5]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[6]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[7]  J. Saba,et al.  Truth and consequences of sphingosine-1-phosphate lyase. , 2012, Advances in biological regulation.

[8]  Ashok Kumar,et al.  The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. , 2011, Cellular signalling.

[9]  J. Trojanowski,et al.  BACE1 Activity Is Modulated by Cell-Associated Sphingosine-1-Phosphate , 2011, The Journal of Neuroscience.

[10]  S. Pitson.  Regulation of sphingosine kinase and sphingolipid signaling. , 2011, Trends in biochemical sciences.

[11]  C. Duyckaerts,et al.  Local cholesterol increase triggers amyloid precursor protein‐Bacel clustering in lipid rafts and rapid endocytosis , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[13]  Michael I. Miller,et al.  Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss , 2010, Alzheimer's & Dementia.

[14]  Constantine G. Lyketsos,et al.  Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets? , 2010, NeuroMolecular Medicine.

[15]  Cheng Luo,et al.  SPHINGOSINE-1-PHOSPHATE: A MISSING COFACTOR FOR THE E3 UBIQUITIN LIGASE TRAF2 , 2010, Nature.

[16]  P. Codogno,et al.  Regulation of cell death by sphingosine 1-phosphate lyase , 2010, Autophagy.

[17]  C. Gong,et al.  Deregulation of sphingolipid metabolism in Alzheimer's disease , 2010, Neurobiology of Aging.

[18]  C. Lyketsos,et al.  Serum sphingomyelins and ceramides are early predictors of memory impairment , 2010, Neurobiology of Aging.

[19]  Cheng Luo,et al.  Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate , 2009, Science.

[20]  Steven J Brown,et al.  Sphingosine 1-phosphate receptor signaling. , 2009, Annual review of biochemistry.

[21]  W. Klein,et al.  Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.

[22]  Marie-Claude Potier,et al.  Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.

[23]  J. Troncoso,et al.  ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain , 2009, Neurobiology of Aging.

[24]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[25]  O. Cuvillier.  Downregulating sphingosine kinase-1 for cancer therapy. , 2008, Expert opinion on therapeutic targets.

[26]  T. Hartmann,et al.  Alzheimer’s disease: the lipid connection , 2007, Journal of neurochemistry.

[27]  S. Milstien,et al.  Autocrine and paracrine roles of sphingosine-1-phosphate , 2007, Trends in Endocrinology & Metabolism.

[28]  M. Gill,et al.  Association studies of 23 positional/functional candidate genes on chromosome 10 in late‐onset Alzheimer's disease , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[29]  M. Maddelein,et al.  Critical Role for Sphingosine Kinase-1 in Regulating Survival of Neuroblastoma Cells Exposed to Amyloid-β Peptide , 2007, Molecular Pharmacology.

[30]  I. Funatogawa,et al.  Revisiting the relation between change and initial value: A review and evaluation by Yu‐Kang Tuand Mark S. Gilthorpe, Statistics in Medicine 2006; DOI: 10.1002/sim.2538 , 2007, Statistics in medicine.

[31]  V. Brinkmann.  Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.

[32]  L. Horrocks,et al.  Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide , 2007, Journal of neuroscience research.

[33]  V. Haroutunian,et al.  Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer’s Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer’s Disease? , 2007, Neurochemical Research.

[34]  Yu-Kang Tu,et al.  Revisiting the relation between change and initial value: a review and evaluation , 2007, Statistics in medicine.

[35]  I. Torres-Aleman,et al.  Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: New cues into the human disease? , 2006, Neurobiology of Aging.

[36]  L. Mucke,et al.  Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. , 2006, The Journal of clinical investigation.

[37]  F. Metzger,et al.  Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis , 2006, Neurobiology of Aging.

[38]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[39]  B. Kriem,et al.  Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.

[40]  I. Akiguchi,et al.  Astroglial expression of ceramide in Alzheimer's disease brains: A role during neuronal apoptosis , 2005, Neuroscience.

[41]  J. Wands,et al.  Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.

[42]  I. Torres-Aleman,et al.  The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. , 2004, European journal of pharmacology.

[43]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Xianlin Han,et al.  Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathway , 2004, The Journal of Cell Biology.

[45]  J. Pettegrew,et al.  Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.

[46]  C. Duyckaerts,et al.  Laminar distribution of neocortical senile plaques in senile dementia of the alzheimer type , 2004, Acta Neuropathologica.

[47]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[48]  M. Vadas,et al.  Activation of sphingosine kinase 1 by ERK1/2‐mediated phosphorylation , 2003, The EMBO journal.

[49]  L. Puglielli,et al.  Withdrawal: Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis , 2003, Journal of Biological Chemistry.

[50]  Sarah Spiegel,et al.  Sphingosine-1-phosphate: an enigmatic signalling lipid , 2003, Nature Reviews Molecular Cell Biology.

[51]  L. Puglielli,et al.  Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. , 2003, The Journal of biological chemistry.

[52]  O. Cuvillier.  Sphingosine in apoptosis signaling. , 2002, Biochimica et biophysica acta.

[53]  Xianlin Han,et al.  Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis , 2002, Journal of neurochemistry.

[54]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[55]  S. Milstien,et al.  Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells , 2001, Journal of neurochemistry.

[56]  S. Spiegel,et al.  Sphingosine‐1‐Phosphate in Cell Growth and Cell Death a , 1998, Annals of the New York Academy of Sciences.

[57]  K. Flanders,et al.  TRANSFORMING GROWTH FACTOR-βS IN NEURODEGENERATIVE DISEASE , 1998, Progress in Neurobiology.

[58]  K. Flanders,et al.  Transforming growth factor-betas in neurodegenerative disease. , 1998, Progress in neurobiology.

[59]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[60]  S. Spiegel,et al.  Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate , 1996, Nature.

[61]  H. Brody,et al.  The aging brain , 1992, Acta neurologica Scandinavica. Supplementum.